On February 27, GLONGHUI (002653.SZ) announced that its subsidiary, Sichuan Hisco Pharmaceutical Co., Ltd. (“Sichuan HiCisco”), used its own capital to fund its subsidiary HAISCO HOLDINGS PTE.LTD. (hereinafter referred to as “Hisco Holdings”) increased its capital by 40 million US dollars.
Hisco Holdings increased the capital of its subsidiary Haisco Holdings Group Limited (hereinafter referred to as “Hisco Holding Group”) by US$40 million with its own capital.
HiCisco Holding Group increased the capital of its subsidiary Haisco-USA Pharmaceuticals, Inc. (hereinafter referred to as “American HiCisco”) by US$40 million with its own capital.